NCT05367401 2024-04-11A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS ParticipantsNovartisPhase 1/2 Withdrawn
NCT02678338 2019-02-21CAMELLIA: Anti-CD47 Antibody Therapy in Haematological MalignanciesGilead SciencesPhase 1 Completed20 enrolled